comparemela.com

Latest Breaking News On - European biotech acquisition - Page 2 : comparemela.com

Oculis and European Biotech Acquisition Corp Announce Business Combination Agreement // Cooley // Global Law Firm

Oculis and European Biotech Acquisition Corp Announce Business Combination Agreement // Cooley // Global Law Firm
cooley.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cooley.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomRyan sansomAaron pomeroyMichal berknerOculis holdingEuropean biotech acquisition corpEuropean biotech acquisitionPartners michal berknerDiv gupta

PR News | Consilium Strategic Comms Eyes Oculis Deal

Consilium Strategic Communications is handling the merger of Oculis and European Biotech Acquisition Corp.

David daleyAmber fennellEduardo bravoMatthew coleEuropean biotech acquisition corpConsilium strategic communicationsEuropean biotech acquisitionStrategic communications

European Biotech Acquisition (NASDAQ:EBACU) Trading 0 2% Higher

European Biotech Acquisition Corp. (NASDAQ:EBACU – Get Rating) shares traded up 0.2% during trading on Monday . The company traded as high as $9.84 and last traded at $9.84. 3,265 shares were traded during trading, an increase of 21% from the average session volume of 2,706 shares. The stock had previously closed at $9.82. The […]

Noord hollandSage mountain advisorsWealthspring capitalEuropean biotech acquisition company profileCubist systematic strategiesEuropean biotech acquisition corpEuropean biotech acquisitionGet ratingMahoney asset managementMountain advisorsBiotech acquisition company profileBiotech acquisitionNasdaq ebacu

Schonfeld Strategic Advisors LLC Cuts Stake in European Biotech Acquisition Corp (NASDAQ:EBACU)

Schonfeld Strategic Advisors LLC reduced its position in European Biotech Acquisition Corp. (NASDAQ:EBACU – Get Rating) by 23.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 89,475 shares of the company’s stock after selling 27,018 shares during the quarter. Schonfeld Strategic Advisors […]

Noord hollandSchonfeld strategic advisorsExchange commissionSage mountain advisorsEuropean biotech acquisition corpEuropean biotech acquisitionGet ratingStrategic advisorsMountain advisorsBiotech acquisitionVisit holdingschannelNasdaq ebacuSec filingsHedge fund holdingsInstitutional investor holdings

European Biotech Acquisition Corp Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report

European Biotech Acquisition Corp. Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report European Biotech Acquisition Corp. (the Company ) today announced it received a notice on May 28, 2021 from the Nasdaq Stock Market LLC ( Nasdaq ) indicating that as a result of the Company s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the Quarterly Report ), the Company no longer complies with the continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1). The notice has no immediate impact on the listing of the Company s securities, which will continue to trade on Nasdaq, subject to the Company s compliance with other applicable continued listing requirements.

Exchange commissionNasdaq stock marketPurpose acquisition companies spacs the staff statementEuropean biotech acquisition corpAudit committee of the companyEuropean biotech acquisitionQuarterly reportNasdaq listing ruleReporting considerationsWarrants issuedSpecial purpose acquisition companiesStaff statementChief accountantAudit committeeLate filingBiotech acquisition

vimarsana © 2020. All Rights Reserved.